Tag:
apixaban
Latest Headlines
Latest Headlines
Pfizer, BMS face a delay on FDA's megablockbuster decision on apixaban
Pfizer ( $PFE ) and its partner Bristol-Myers Squibb ( $BMY ) will have to wait before hearing whether the FDA will sign off on marketing approval for apixaban, their blockbuster anti-clotting hopeful.
Pfizer, BMS drug Eliquis gets FDA priority review
The FDA has granted Pfizer ( $PFE ) and Bristol-Myers Squibb ( $BMY ) priority review of the companies' anti-clotting drug Eliquis, promising a final ruling on the drug by March 28. The news comes a day
Pfizer, BMS unveil mega-blockbuster data on apixaban
Continuing its hot streak through the weekend, Pfizer ($PFE) and its partner Bristol-Myers Squibb ($BMY) posted promising late-stage data for apixaban, a bloodthinner with mega-blockbuster potential.
BMS, Pfizer ready key data on closely-watched apixaban
Analysts have been gearing up for the big presentation Bristol-Myers Squibb ( $BMY ) and Pfizer ( $PFE ) will make on late-stage data for apixaban at the upcoming meeting of the European Society of
Pfizer's potential offload of biz units could aid R&D prospects
Pfizer chief Ian Read's ( photo ) strategy to make the drug giant a more focused machine is gaining some kudos--especially as it relates to how this strategy could boost the firm's top pipeline
J&J gets FDA green light for blockbuster blood thinner Xarelto
J&J has scored another big regulatory win, gaining FDA approval late on Friday for Xarelto, a blood clot prevention therapy that has been tapped as one of the drug company's top six new drugs for
Apixaban bests warfarin in head-to-head study
Pfizer and Bristol-Myers Squibb have reason to celebrate today. A late stage study comparing their next-generation blood thinner Eliquis (apixaban) to warfarin demonstrated that the experimental drug
Pfizer, BMS forthcoming data on apixaban has analysts on alert
Wall Street is anxiously awaiting results from a late-stage trial of Pfizer and Bristol-Myers Squibb's next-generation blood thinner, as analysts will be looking closely for how the blockbuster
EU hands Pfizer, BMS an approval for blockbuster apixaban
Pfizer and Bristol-Myers Squibb racked up a key regulatory win on Friday when they announced that their blood thinner apixaban had gained approval in the EU. And analysts expect that the drug--to be
European experts back Pfizer, BMS drug apixaban
Europe's Committee for Medicinal products for Human Use backed the use of Eliquis (apixaban), an anti-clotting drug co-developed by Pfizer and Bristol-Myers Squibb. The treatment is indicated to
